Omnispec Clinical Research Inc, Mirabel, Canada   Report issue

For profit Phase 2 Phase 3
Founded: Montreal Canada (2005)

Organization Overview

First Clinical Trial
2007
NCT00419263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Omnispec clinical research Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

trigonellamide (1 trial)

Drugs in Phase 2 Trials (4)

flulaval (1 trial)

inactivated influenza vaccine (1 trial)

influenza vlp vaccine (1 trial)

peramivir (rapivab) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hypertriglyceridemia (Phase 3)

Infections (Phase 2)

Influenza, Human (Phase 2)

Respiratory Tract Diseases (Phase 2)

Respiratory Tract Infections (Phase 2)

RNA Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5